-11%-11%
Availability: Άμεσα Διαθέσιμο

Heart Disease: A Multidisciplinary Approach, 1st Edition. Clinics Collections

Joel J. Heidelbaugh
ISBN: 9780443129391
ISBN: 9780443129391
Εκδόσεις:
Διαστάσεις 23 × 15 cm
Μορφή

Εκδόσεις

Ημ. Έκδοσης

Σελίδες

Έκδοση

Κύριος Συγγραφέας

Original price was: 56,00€.Η τρέχουσα τιμή είναι: 50,00€.(Περιλαμβάνεται ΦΠΑ 6%)

Διαθέσιμο - Προπαραγγελία|Διαθεσιμότητα: 11-14 ημέρες

Κατηγορία:

Περιγραφή

Clinics Collections: COVID-19 draws from Elsevier’s robust Clinics
Review Articles database to provide multidisciplinary teams, including
pediatricians, primary care physicians, and cardiologists, with practical
clinical advice and insights from the COVID-19 pandemic and its impact
across individual specialties.
Clinics Collections: COVID-19 guides readers on how to apply
current best practices in the diagnosis and treatment of COVID-19
and associated comorbidities to everyday practice to help overcome
challenges and complications, keep up with new and advanced treatment
methods, and improve patient outcomes.
Author Information
Edited by Joel J. Heidelbaugh, MD, FAAFP, FACG, Clinical Professor Departments of Family Medicine and Urology University of Michigan Medical School Ann Arbor, Michigan

Περιεχόμενα

  • Cover image
  • Title page
  • Table of Contents
  • Contributors
  • Preface
  • Pediatric Heart Disease
  • Congenital Heart Disease
  • Key points
  • Introduction
  • Cause of congenital heart disease
  • Prenatal diagnosis of congenital heart disease
  • Normal fetal and transitional circulation
  • Pulse oximetry screening
  • Neonatal presentations of congenital heart disease
  • Neonatal congenital heart disease requiring emergent intervention
  • Ductal-dependent lesions not requiring emergent intervention
  • Other neonatal congenital heart disease presentations
  • Longitudinal follow-up issues in the child with congenital heart disease
  • Summary
  • Clinics care points
  • Pediatric Hypertension
  • Key points
  • Introduction
  • Etiology and risk factors for development
  • Evaluation
  • Management
  • Discussion
  • Clinics care points
  • Preparticipation Cardiac Evaluation from the Pediatric Perspective
  • Key points
  • Introduction
  • Cases
  • What is the purpose of preparticipation evaluation?
  • Differences in incidence and causes of sudden cardiac arrest
  • Differences in phenotype presentation
  • Who should be evaluated and when should it start?
  • Where do preparticipation evaluations occur?
  • The components of the preparticipation evaluation
  • Summary
  • Clinics care points
  • Disclosures
  • The Risk of Sudden Unexpected Cardiac Death in Children: Epidemiology, Clinical Causes, and Prevention
  • Key points
  • Introduction
  • Epidemiology
  • Causes
  • Prevention
  • Summary
  • Clinics care points
  • Disclosure
  • Adult Heart Disease
  • Assessment of Cardiovascular Disease Risk: A 2022 Update
  • Key points
  • Introduction
  • Atherosclerotic cardiovascular disease risk assessment
  • Traditional atherosclerotic cardiovascular disease risk calculators
  • Risk-enhancing factors
  • Atherosclerosis imaging
  • Advanced lipid testing
  • Endocrine Society’s 2020 Lipid Management Guideline
  • Future directions
  • Clinics care points
  • Race and Modifiable Factors Influencing Cardiovascular Disease
  • Key points
  • Introduction
  • Summary
  • Clinics Care Points
  • Cardiovascular Disease in Older Women
  • Key points
  • Introduction
  • Incidence and risk
  • Pregnancy related
  • Autoimmune diseases
  • Breast cancer
  • Polycystic ovary syndrome
  • Menopause
  • Traditional risk factors
  • Diabetes
  • Smoking and obesity
  • Hyperlipidemia
  • Hypertension
  • Testing
  • Exercise treadmill stress test
  • Echocardiogram
  • Myocardial perfusion imaging
  • Cardiac MRI
  • Cardiac computed tomography
  • Therapeutics
  • Summary
  • Clinics care points
  • Drug Interactions: What Are Important Drug Interactions for the Most Commonly Used Medications in Preventive Cardiology?
  • Key points
  • Introduction
  • Discussion
  • Summary
  • Clinics care points
  • Heart-Healthy Diets and the Cardiometabolic Jackpot
  • Key points
  • Introduction
  • Discussion: heart-healthy diet guidelines
  • Current evidence on popular diets
  • The cardiometabolic jackpot
  • Special considerations
  • Summary
  • Clinics care points
  • Supplementary data
  • The Role of Physical Activity and Exercise in Preventive Cardiology
  • Key points
  • Introduction
  • Physical activity, exercise, and cardiorespiratory fitness
  • Physical activity and decreased atherosclerotic vascular disease risk
  • How does physical activity reduce coronary artery disease events?
  • Exercise effects on atherosclerotic vascular disease risk factors
  • Exercise-based cardiac rehabilitation
  • Clinics care points
  • Management of Coronary Artery Disease
  • Key points
  • Background
  • Patient evaluation and overview
  • Determination of pretest risk
  • Approach to testing
  • Exercise versus pharmacologic testing
  • Testing modalities
  • Medical treatment options
  • Surgical and interventional treatment options
  • Combined therapy
  • Treatment failure and complications
  • Innovative approaches and new developments
  • Evaluation of outcome and long-term recommendations
  • Summary
  • Clinics care points
  • Approach to the Patient with a Murmur
  • Key points
  • Introduction
  • Auscultation in valvular heart disease
  • Clinics care points
  • Summary
  • Supplementary data
  • Medical Management of Peripheral Artery Disease
  • Key points
  • Introduction
  • Smoking cessation
  • Lipid-lowering therapy
  • Hypertension
  • Antiplatelet and antithrombotic therapy
  • Other therapies
  • Future directions
  • Summary
  • Clinics care points
  • Disclosure
  • The Effects of Testosterone Treatment on Cardiovascular Health
  • Key points
  • Introduction
  • Physiologic effects of testosterone on cardiovascular health
  • Effects of testosterone on blood pressure
  • Effects of testosterone on serum lipid parameters
  • Effects of Testosterone on Venous Thromboembolism
  • Effects of testosterone on glucose intolerance and type 2 diabetes
  • The effects of testosterone treatment on the risk of major adverse cardiovascular events
  • Summary
  • Clinics care points
  • Obstructive Sleep Apnea and Cardiovascular Disease
  • Key points
  • Introduction and background
  • Prevalence of obstructive sleep apnea
  • Pathophysiology of cardiovascular disease with obstructive sleep apnea
  • Clinical presentation of obstructive sleep apnea with cardiovascular disease
  • Impact of treatment of obstructive sleep apnea on cardiovascular disease
  • Electrophysiological effects of obstructive sleep apnea
  • Sinus node dysfunction, atrioventricular block, and obstructive sleep apnea
  • Clinics care points
  • Management of Dyslipidemia in Endocrine Diseases
  • Key points
  • Introduction/history/definitions/background
  • Case study
  • Discussion
  • Other lipid-influencing endocrine diagnoses
  • Summary
  • Clinics care points
  • Role of Lipid Management in Women’s Health Preventive Care
  • Key points
  • Introduction
  • Pregnancy
  • Polycystic ovarian syndrome
  • Contraception
  • Menopause transition
  • Summary
  • New and Emerging Therapies for Dyslipidemia
  • Key points
  • Introduction
  • Patients with atherosclerotic cardiovascular disease or atherosclerotic cardiovascular disease risk equivalent and elevated level of LDL-C (Orion-1, -10, and -11)
  • Patients with homozygous hypercholesterolemia (Orion-2) and heterozygous hypercholesterolemia (Orion-9)
  • Selective peroxisome proliferator–activated receptor alpha modulators
  • Apolipoprotein C-III targeting approaches
  • Angiopoietin-like protein 3 targeting approaches
  • Lipoprotein (a)-lowering approaches: antisense oligonucleotide and small interfering RNA against apolipoprotein (a)
  • Summary
  • Clinics care points
  • LDL Cholesterol—How Low Can We Go?
  • Key points
  • Introduction
  • Cholesterol transport
  • Low cholesterol states
  • Utility of reducing LDL-C below 40 mg/dL
  • Discussion
  • Summary
  • Clinical pearls
  • Disclosure
  • High-Density Lipoprotein and Cardiovascular Disease—Where do We Stand?
  • Key points
  • Introduction. Brief history of high-density lipoprotein discovery, nomenclature, and complexity
  • High-density lipoprotein metabolism
  • Mechanisms by which high-density lipoprotein might be atheroprotective
  • Epidemiology and genetics of high-density lipoprotein in relation to cardiovascular disease
  • Inherited disorders of high-density lipoprotein metabolism and their relationship to atherosclerosis
  • Fibrates
  • Niacin
  • Cholesteryl ester transfer protein inhibitors
  • Apolipoprotein A-I infusions
  • Apolipoprotein A-I mimetics
  • Where do we go from here?
  • Clinics care points
  • Disclosure
  • Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction
  • Key points
  • Introduction
  • Diverse pathophysiology of heart failure with preserved ejection fraction and its phenotype
  • Efforts to increase the accuracy of heart failure with preserved ejection fraction diagnosis
  • Pharmacologic and nonpharmacologic treatment
  • Summary
  • Clinics care points
  • Telehealth in Heart Failure
  • Key points
  • Introduction
  • Summary
  • Clinics care points
  • Hypertension and Heart Failure: Prevention, Targets, and Treatment
  • Key points
  • Introduction
  • Epidemiology
  • From hypertension to heart failure
  • Blood pressure targets
  • Pharmacotherapy
  • Lifestyle modifications
  • Summary
  • Atrial Fibrillation and Heart Failure: Epidemiology, Pathophysiology, Prognosis, and Management
  • Key points
  • Introduction
  • Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction
  • Epidemiology of atrial fibrillation–heart failure
  • Pathophysiology of atrial fibrillation–heart failure
  • Shared risk factors
  • Heart failure promotes incident atrial fibrillation
  • Atrial fibrillation promotes incident heart failure
  • Prognostic implications of atrial fibrillation–heart failure
  • Atrial fibrillation and heart failure with midrange ejection fraction
  • Management of atrial fibrillation–heart failure
  • Management of atrial fibrillation–heart failure with reduced ejection fraction
  • Management of atrial fibrillation–heart failure with preserved ejection fraction
  • Summary
  • Clinics Care Points
  • FINANCIAL DISCLOSURES
  • CONFLICT OF INTEREST DISCLOSURES
  • Atrial Fibrillation in Valvular Heart Disease
  • Key points
  • Prevalence of rheumatic heart disease
  • Prevalence of atrial fibrillation in rheumatic heart disease
  • Incidence of atrial fibrillation in rheumatic heart disease
  • Sequel of atrial fibrillation
  • Asymptomatic atrial fibrillation in rheumatic heart disease
  • Predictors for atrial fibrillation in rheumatic heart disease
  • Structurally remodeling in mitral stenosis
  • Electroanatomical remodeling of the atria in rheumatic mitral stenosis
  • Acute effects reversal of chronic atrial stretch reversal on left and right atrial electrical remodeling
  • Long-term effects of chronic atrial stretch reversal
  • Spatiotemporal organization and electrogram fractionation
  • Remodeling of pulmonary veins due to chronic stretch
  • Summary
  • The Cardiorenal Syndrome in Heart Failure
  • Key points
  • Introduction
  • Epidemiologic and prognostic considerations
  • Mechanisms of fluid accumulation in heart failure and the cardiorenal syndrome
  • Pathophysiologic events in the kidney in the setting of heart failure
  • Contributions of the abdominal circulation to the cardiorenal syndrome in heart failure
  • Methods for the assessment of fluid volume in the cardiorenal syndrome occurring in heart failure
  • Refractoriness to diuretics in heart failure
  • Extracorporeal ultrafiltration
  • Novel strategies to overcome diuretic resistance
  • Summary

Σχετικά προϊόντα